SCHEMBL8261472

SCHEMBL8261472

CS(=O)(=O)c1ccc(NC(=O)c2n[nH]cc2NC(=O)c2c(Cl)cccc2Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK14 O94921 8/20 0.58
▸ CCNY Q8ND76 8/20 0.58
▸ KMT2A Q03164 1/20 0.53
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ITGB1 P05556 1/20 0.46
▸ ITGA4 P13612 1/20 0.46
▸ TYK2 P29597 2/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ JAK1 P23458 1/20 0.45
▸ AVPR2 P30518 1/20 0.45
▸ GPR27 Q9NS67 1/20 0.45
▸ FAAH O00519 2/20 0.44
▸ MGLL Q99685 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.43
▸ TAS1R1 Q7RTX1 1/20 0.43
▸ TAS1R2 Q8TE23 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8261470 0.85 CDK14 (0.53) CDK14CCNYKMT2ACYP3A4TYK2
SCHEMBL8212885 0.83 TYK2 (0.68) CDK14CCNYKMT2ACYP3A4TYK2
SCHEMBL23271061 0.81 CDK14 (0.65) CDK14CCNYCYP3A4TYK2JAK2
SCHEMBL13993632 0.80 CDK14 (0.56) CDK14CCNYCYP3A4TYK2JAK2
SCHEMBL954966 0.80 CDK14 (0.55) CDK14CCNYCYP3A4TYK2JAK2
SCHEMBL1070972 0.80 KMT2A (0.55) CDK14CCNYKMT2ACYP3A4TYK2
SCHEMBL8261502 0.80 CDK14 (0.55) CDK14CCNYCYP3A4TYK2JAK2
SCHEMBL959301 0.79 POLB (0.56) CDK14CCNYKMT2AALDH1A1
SCHEMBL12288164 0.79 CDK14 (0.53) CDK14CCNYKMT2ACYP3A4TYK2
SCHEMBL13993628 0.79 LCK (0.61) CDK14CCNYGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 — — US disclosed
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 — — US disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S GSK3A, CDK11A, CDK1 CDK14 8/4885CCNY 51/4885KMT2A 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback